Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 3Stomach Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Vomiting 1Substance-Related Disorders 1Solid Tumors 1Recurrence 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Opioid-Related Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma 1Low Anterior Resection Syndrome 1Colonic Neoplasms 1Acromegaly 1

Interventions

Gemcitabine 9Paclitaxel 8Carboplatin 7atezolizumab 6Sunitinib 5navitoclax 4Topotecan 4Irinotecan 4Docetaxel 4Bevacizumab 4pazopanib 3liposomal doxorubicin 3cobimetinib 3Nivolumab 3Erlotinib Hydrochloride 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2temsirolimus 2selicrelumab 2plocabulin 2envafolimab 2darinaparsin 2brigimadlin 2adavosertib 2Tablets 2Sorafenib 2Rifampin 2RG7388 2Panitumumab 2NVP-BKM120 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumors × Dosage Forms × Clear all
NCT00125827 2014-03-19

Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

Sanofi

Phase 1 Completed
24 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡